Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry
NCT ID: NCT06172426
Last Updated: 2023-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1171 participants
OBSERVATIONAL
2022-11-17
2022-12-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MarketScan® secukinumab, other biologics/apremilast, and any biologics/apremilast cohort
No interventions assigned to this group
BADBIR secukinumab cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Included patients age ≥18 years as of the year of index date
* Included patients with at least 1 non-ruleout psoriasis diagnosis during 2 years of pre-index period
* Included patients with continuous medical/pharmacy coverage in the 2-year pre-index period
* Included patients with continuous medical/pharmacy coverage in the 1-year post-index period
* Included non-switched patients with secukinumab treatment on or after the enrollment between 01 January 2017 to 01 September 2020
* Non-switched patients are those who did not use other biologics/apremilast treatments on the enrollment date
* Index date will be the date of the first secukinumab treatment date
* Included patients with age ≥ 18 on the index date
* Included patients with psoriasis diagnosis in the pre-index period and index date
* Included patients with ≥ 1 year follow-up period
* Follow-up period is the gap between patient's last visit date and index date
Exclusion Criteria
* Excluded patients with any biologics/apremilast including secukinumab claim during the 2-year pre-index (excluding index date)
* Excluded patients received other non-secukinumab biologics/apremilast during 6 months post index date period (including index date) (This criterion is only applicable for the secukinumab cohort)
BADBIR cohort:
* Excluded patients with psoriatic arthritis (PsA) prior to and on index date
* Excluded patients with any biologics/apremilast including secukinumab in the baseline period
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAIN457A2026
Identifier Type: -
Identifier Source: org_study_id